Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for NK-mediated Rejection in Kidney Transplant Patients
NCT03955172Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of everolimus in kidney transplant rejection, sponsored by Hospices Civils de Lyon. Primary endpoint: Estimated glomerular filtration rate at 6 months. Started Dec 2020; status: recruiting.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03955172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955172.